The study, conducted at the USC Stem Cell laboratory of Ksenia Gnedeva, PhD, focuses on the biological barriers that prevent humans and other mammals from repairing sensory receptors after injury. Unlike certain species of fish and birds that can naturally regenerate lost hearing or sight, mammals are born with a fixed number of sensory hair cells in the ear and photoreceptors in the eye. Once these cells are damaged by age, noise, trauma, or disease, the loss is typically permanent. The findings from the Gnedeva lab suggest that this regenerative "block" is not an absence of potential, but rather an active suppression governed by a specific set of genes.
The Biological Barrier to Sensory Recovery
The core of the research involves the Hippo pathway, a complex signaling network that regulates organ size and cell proliferation during embryonic development. In the context of the inner ear and the retina, the Hippo pathway functions as a "stop growing" signal. While this signal is essential for ensuring that organs do not overgrow during gestation, it remains active in adulthood, preventing the body from producing new sensory cells to replace damaged ones.
"The proliferation of progenitor cells in response to injury is a crucial step in the regeneration of sensory receptors, but this process is blocked in the mammalian inner ear and retina," explained Dr. Ksenia Gnedeva, an assistant professor in the USC Tina and Rick Caruso Department of Otolaryngology – Head and Neck Surgery. "By understanding the genes that enforce this block, we can advance efforts to restore hearing and vision in patients."
In the mammalian ear, the sensory receptors are known as hair cells, located within the cochlea. In the eye, the retina contains photoreceptors that convert light into neural signals. In both organs, these receptors are supported by "progenitor cells"—specialized cells that retain the potential to divide and transform into sensory receptors under the right conditions. However, in adult mammals, the Hippo pathway keeps these supporting cells in a state of dormancy.
Experimental Breakthroughs: Overcoming the Hippo Pathway
The study, led by first authors Eva Jahanshir and Juan Llamas, utilized a multi-phase experimental approach to test whether inhibiting the Hippo pathway could "unlock" the regenerative potential of these organs. The researchers focused on Lats1/2, a pair of key proteins within the Hippo pathway that act as the primary inhibitors of cell division.
Initially, the team used a drug-like experimental compound developed in the Gnedeva lab to inhibit Lats1/2 in a controlled laboratory environment. When adult mouse cells were exposed to this compound in a Petri dish, the researchers observed a striking difference in response between different parts of the ear. Progenitor cells (supporting cells) in the utricle—the sensory organ responsible for balance—began to proliferate rapidly. However, the same cells in the organ of Corti, which is the primary sensory organ for hearing, showed no response.
This discrepancy led the team to investigate why the organ of Corti remained resistant to regeneration even when the Hippo pathway was inhibited. Their search identified a secondary "brake": a protein-encoding gene called p27Kip1. This protein acts as a cyclin-dependent kinase inhibitor, effectively locking cells in a non-dividing state. The researchers discovered that while the Hippo pathway is a major regulator, p27Kip1 provides a redundant layer of suppression in the hearing organ and the retina.
Transgenic Modeling and Dual-Target Success
To test the hypothesis that both the Hippo pathway and p27Kip1 must be addressed to achieve regeneration, the scientists engineered a transgenic mouse model. This model allowed the researchers to precisely reduce the levels of p27Kip1 in the inner ear and retina while simultaneously inhibiting the Hippo pathway.
The results in the transgenic mice were transformative. With the levels of p27Kip1 reduced, inhibiting the Hippo pathway successfully induced the proliferation of supporting cells within the organ of Corti. This represented a major step toward the eventual regeneration of hearing-related hair cells.
Even more surprising were the results observed in the retina. In the eye, the primary progenitor cells are known as Müller glia. Under normal conditions, these cells provide structural and metabolic support to the retina but do not divide to replace lost neurons. By inhibiting the Hippo pathway and reducing p27Kip1, the researchers triggered the proliferation of Müller glia. Remarkably, the study found that some of these newly created cells spontaneously converted into sensory photoreceptors and other vital neuronal cell types without any further genetic or chemical manipulation.
"There have been reports that p27Kip1 levels drop following injury, so that might offer a brief window of opportunity for using a drug-like compound to inhibit the Hippo pathway and encourage regeneration in the ear and the eye," noted Dr. Gnedeva.
Clinical Implications and the Future of Sensory Medicine
The implications of this research for human health are profound. According to the World Health Organization (WHO), over 1.5 billion people globally live with some degree of hearing loss, a number expected to rise to 2.5 billion by 2050. Similarly, vision loss affects millions, with retinal degenerative diseases often leading to irreversible blindness.
Current treatments, such as hearing aids, cochlear implants, or visual prosthetics, focus on compensating for the loss of sensory cells rather than repairing the underlying biological damage. The USC study points toward a future of "regenerative pharmacology," where drugs could be used to temporarily silence the Hippo pathway and p27Kip1 to allow the body to heal itself.
The research also highlights a potential timeline for treatment. Because p27Kip1 levels naturally fluctuate following an acute injury, there may be a "therapeutic window" where the administration of a Hippo-inhibiting drug could be most effective. Alternatively, the development of a secondary compound to specifically lower p27Kip1 could provide a dual-therapy approach for chronic cases.
Scientific Context and Collaborative Support
This study builds upon years of research into the Hippo pathway’s role in development. Previous work by the Gnedeva lab had already established that this pathway inhibits cell proliferation during the embryonic stages of ear development. By proving that the same mechanism persists into adulthood and applies to both the ear and the eye, the team has unified two previously separate fields of sensory research.
The research was a collaborative effort within the Gnedeva Lab at USC, with contributions from co-authors Yeeun Kim, Kevin Biju, and Sanyukta Oak. The work was supported by substantial federal funding from the National Institutes of Health’s (NIH) National Institute on Deafness and Other Communication Disorders (NIDCD), including grants 1R01DC020268, T32DC009975, and 5R25DC019700.
Intellectual Property and Commercial Path
The commercial potential of these findings is already being secured through the patent process. Dr. Gnedeva is listed as a co-inventor on three patent applications related to this research, signaling a clear path toward clinical development. These include:
- A Lats kinase inhibitor specifically designed to treat retinal degeneration (PCT/US2024/023146).
- Compositions and methods involving pyrrolopyridine-3- and 4-carboxamide for stimulating cellular proliferation.
- Specific compositions aimed at ameliorating hearing loss through the pyrrolo[2,3-b]pyridine-3-carboxamide pathway.
As the research moves from mouse models toward potential human trials, the focus will shift to the safety and delivery of these compounds. Targeting specific cells in the inner ear and retina requires precise delivery mechanisms, such as local injections or specialized viral vectors, to avoid systemic side effects.
The discovery that the same genetic "brakes" control regeneration in both the eye and the ear suggests that sensory restoration may not require a different solution for every organ. Instead, a master key—targeting the Hippo pathway and p27Kip1—could eventually provide a universal treatment for the millions of individuals suffering from sensory impairment. By dismantling the evolutionary barriers that prevent mammals from regenerating their most vital sensory cells, the USC team has opened a new chapter in the quest to cure deafness and blindness.
